NImmune Biopharma ("NImmune"), a private late-stage precision inflammation and immunology ("I&I") biopharmaceutical company, ...
Gilead Sciences, Inc. today announced details of new clinical and real-world data from its innovative HIV treatment and ...
Entered 2026 With a Strong Commercial Momentum Expects Q1 2026 Revenue to Grow over 100% as Compared to Q1 2025Reaffirms FY 2026 Guidance with Revenue Expected to Grow Between 50%-100% Year Over Year ...
PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results